The theme for this year’s three-part series is neglected tropical diseases, which comprise a set of 20 diseases afflicting more than 1.9 billion people worldwide. These individuals are the poorest of the poor and mostly reside in areas of low-income countries that lack safe water and adequate sanitation.
A King's College collaboration with the Cambridge-Africa Programme and Wellcome Trust-Cambridge Centre for Global Health Research
Topic: Access to medicines for neglected tropical diseases
Format: Panel discussion/debate
Date: February 8, 2018
Prof. Don Bundy – London School of Tropical Medicine & Hygiene; Children’s Investment Fund
Prof. Peter Hotez – Dean for the National School of Tropical Medicine at the Baylor College of Medicine, USA; Professor of Tropical Pediatrics
Mr. Andy Wright – Vice President of Global Health and Access Programmes at GlaxoSmithKline
Dr. Jutta Reinhard-Rupp – Head of Merck Global Health Institute
Mr. Julien Potet – Médecins Sans Frontières (MSF) Policy advisor for NTDs & vaccines in MSF’s Access to Medicine Campaign
Dr. Fiona Godlee – Editor-in-Chief of the British Medical Journal
Topic: How do we eliminate a disease of poverty?
Format & Date: Seminar; October 5, 2017
Speaker: Prof. David Molyneux, Liverpool School of Tropical Medicine
Talk title: Neglected Tropical Diseases: the challenges of elimination in a changing world
Abstract: Neglected Tropical Diseases (NTDs) have been included within the Health Targets of the United Nations Sustainable Development Goals, recognizing their impact as impediments to health of the poorest 1-2 billion. Over the past decade there has been increased resources to implement NTD programmes and for both basic and operational research reflecting the need for new tools but also the need to address the challenges of increasing uptake of donated medicines in complex and diverse settings. The World Health Organization created a Roadmap in 2012 to achieve certain targets for elimination and eradication by 2020. The challenges that elimination programmes face and the research required to accelerate progress will be discussed in the light of geopolitical events, environmental change, competition for health resources as health policy changes and new biological information—all factors which impact on rapidly approaching targets. The elimination “end game” and eradication defined as “zero global incidence of infection” poses a unique challenge, i.e. how do we prove a negative? This target must be achieved in remote, conflict affected and geographically difficult regions with limited health services and communication. This talk will discuss the success to date, the research required to address the challenges and the current global health policy environment.
Dr. Goylette Chami
Junior Research Fellow in Medical Sciences